Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1971532
Sentiment: neutral
Topics: 8-k, sec-filing, other-events
TL;DR
Telomir Pharma filed an 8-K on 12/2/24 for 'Other Events' - details TBD.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on December 2, 2024, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. The company is incorporated in Florida and its principal executive offices are located in Miami.
Why It Matters
This 8-K filing indicates that Telomir Pharmaceuticals has reported an event requiring immediate disclosure to the SEC, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events' without immediate specific details, creating uncertainty about the nature and impact of the reported event.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- December 2, 2024 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- Miami (location) — Address of Principal Executive Offices
- 87-2606031 (other) — IRS Employer Identification No.
- 001-41952 (other) — Commission File Number
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 2, 2024.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive office address is 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131.
In which state is Telomir Pharmaceuticals, Inc. incorporated?
Telomir Pharmaceuticals, Inc. is incorporated in Florida.
What is the telephone number for Telomir Pharmaceuticals, Inc.?
The registrant's telephone number, including area code, is (813) 864-2558.
Filing Stats: 744 words · 3 min read · ~2 pages · Grade level 15.6 · Accepted 2024-12-02 16:01:19
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-24-048285.txt ( ) — 217KB
- telo-20241202.xsd (EX-101.SCH) — 3KB
- telo-20241202_lab.xml (EX-101.LAB) — 33KB
- telo-20241202_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Date: December 2, 2024 By: /s/ Erez Aminov Erez Aminov Chief Executive Officer